556 related articles for article (PubMed ID: 9313044)
21. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
[TBL] [Abstract][Full Text] [Related]
22. [Predictive value of the serum PSA level in patients having undergone neo-adjuvant hormone treatment before radical prostatectomy].
Wildschutz T; Janssen T; Schulman C
Acta Urol Belg; 1995 Mar; 63(1):79-82. PubMed ID: 7537012
[TBL] [Abstract][Full Text] [Related]
23. No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer.
Noguchi M; Noda S; Nakashima O; Kojiro M
Oncol Rep; 2002; 9(5):1075-80. PubMed ID: 12168076
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
[TBL] [Abstract][Full Text] [Related]
25. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
26. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
27. [Clinical impact of neoadjuvant treatment to radical prostatectomy in locally advanced prostatic cancer].
Villavicencio H; Laguna P; Ponce de Léon J
Actas Urol Esp; 1994 May; 18 Suppl():404-8. PubMed ID: 8073926
[TBL] [Abstract][Full Text] [Related]
28. [Radical prostatectomy after complete androgen blockade in stage B2 and C cancer].
Peyrottes A; Benizri E; Chevallier D; Volpe P; Michiels JF; Amiel J; Toubol J
J Urol (Paris); 1994; 100(6):290-3. PubMed ID: 7745257
[TBL] [Abstract][Full Text] [Related]
29. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
30. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer.
Kurek R; Renneberg H; Lübben G; Kienle E; Tunn UW
Eur Urol; 1999; 35 Suppl 1():27-31. PubMed ID: 10081700
[TBL] [Abstract][Full Text] [Related]
31. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
Zincke H; Lau W; Bergstralh E; Blute ML
J Urol; 2001 Dec; 166(6):2208-15. PubMed ID: 11696737
[TBL] [Abstract][Full Text] [Related]
32. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?
King CR; Presti JC; Gill H; Brooks J; Hancock SL
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):341-7. PubMed ID: 15145146
[TBL] [Abstract][Full Text] [Related]
33. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
34. Prostate specific antigen doubling time after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy.
Rabbani F; Perrotti M; Bastar A; Fair WR
J Urol; 1999 Mar; 161(3):847-52. PubMed ID: 10022699
[TBL] [Abstract][Full Text] [Related]
35. Effects of androgen deprivation prior to radical prostatectomy in 375 patients.
Tunn UW; Acar O; Goldschmidt AJ
Urol Int; 1996; 56 Suppl 1():6-12. PubMed ID: 8776811
[TBL] [Abstract][Full Text] [Related]
36. [Histologic regression of localized prostatic tumor with neoadjuvant hormonal therapy].
López López C; Quilez Fenoll JM; Gómez Ruiz JJ; López López AF; Romero Maroto YJ
Arch Esp Urol; 1996 Oct; 49(8):819-23. PubMed ID: 9065279
[TBL] [Abstract][Full Text] [Related]
37. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy.
Wood DP; Beaman A; Banerjee M; Powell I; Pontes E; Cher ML
Clin Cancer Res; 1998 Sep; 4(9):2119-23. PubMed ID: 9748128
[TBL] [Abstract][Full Text] [Related]
38. Estimation of total PSA with a supersensitive PSA-assay during neo-adjuvant-chemotherapy of prostate cancer before radical resection of prostate.
Spitz J; Enzmann T; Müller W; Weidenfeld M; Köllermann M
Anticancer Res; 1999; 19(4A):2637-40. PubMed ID: 10470209
[TBL] [Abstract][Full Text] [Related]
39. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D
J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288
[TBL] [Abstract][Full Text] [Related]
40. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
